These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12376035)

  • 1. Fluoroquinolones for the treatment of outpatient community-acquired pneumonia.
    Jones RN; Mandell LA
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):69-76. PubMed ID: 12376035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
    Nicholson SC; Wilson WR; Naughton BJ; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):117-25. PubMed ID: 12376041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
    Mandell LA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042
    [No Abstract]   [Full Text] [Related]  

  • 7. Community-acquired lower respiratory tract infections: etiology and treatment.
    Guthrie R
    Chest; 2001 Dec; 120(6):2021-34. PubMed ID: 11742937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
    Mandell LA
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):65-7. PubMed ID: 12376034
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
    Nicholson SC; High KP; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-Acquired Pneumonia in Adults: Diagnosis and Management.
    Kaysin A; Viera AJ
    Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
    Franca SA; Carvalho CR
    Braz J Infect Dis; 2002 Aug; 6(4):157-63. PubMed ID: 12204182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR; Labreche MJ; Attridge RT
    Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
    Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guiding Principles for the use of Fluroquinolones in Out-patient Community Settings of India: Panel Consensus.
    Vora A; Krishnaprasad K
    J Assoc Physicians India; 2017 Aug; 65(8):51-52. PubMed ID: 28799307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
    Garin N; Nendaz M
    Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparfloxacin empirical therapy in community-acquired pneumonia. Results of a meta-analysis of 2 comparative studies.
    Grassi GG; Brumpt I
    Drugs; 1995; 49 Suppl 2():406-8. PubMed ID: 8549379
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluoroquinolones for respiratory infections: too valuable to overuse.
    Williams JH
    Chest; 2001 Dec; 120(6):1771-5. PubMed ID: 11742900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.